Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial
Armin Riecke, Sandra Robrecht, Deyan Y. Yosifov, Christof Schneider et autres
1 citationBlood
Deyan Y. Yosifov
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
40Publications signalées
542Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentGlycosylation and Glycoproteins ResearchImmunodeficiency and Autoimmune DisordersMultiple Myeloma Research and Treatments
Publications récentes
PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia
Jialei Qi, Wen Li, Rashmi Priyadharshini Dheenadayalan, Deyan Y. Yosifov et autres
0 citationsBlood Advances
IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL
Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Palash C. Maity et autres
0 citationsHemaSphere
Genotyping from targeted NGS data based on a small set of SNPs correctly matches patient samples
Deyan Y. Yosifov, Christof Schneider, Stephan Stilgenbauer, Daniel Mertens et autres
1 citationBMC Research Notes
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL
Alena Sophie Ehrmann, Miguel Quijada‐Álamo, Viola Close, Min Guo et autres
5 citationsLeukemia
Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study
Billy Michael Chelliah Jebaraj, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider et autres
0 citationsBlood
Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents
Rashmi Priyadharshini Dheenadayalan, Deyan Y. Yosifov, Jialei Qi, Christof Schneider et autres
1 citationBlood
repDilPCR: a tool for automated analysis of qPCR assays by the dilution-replicate method
Deyan Y. Yosifov, Michaela Reichenzeller, Stephan Stilgenbauer, Daniel Mertens
0 citationsBMC Bioinformatics
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia
Philipp M. Roessner, Isabelle Seufert, Vicente Chapaprieta, Ruparoshni Jayabalan et autres
7 citationsBlood
Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial
Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider et autres
1 citationBlood
IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial
Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Armin Riecke et autres
1 citationBlood
P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
Deyan Y. Yosifov, Julia von Tresckow, Adam Giza, Sandra Robrecht et autres
0 citationsHemaSphere
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.